Sulfacetamide Sodium and Prednisolone Sodium Phosphate · SULFACETAMIDE SODIUM 100 mg/mL; PREDNISOLONE SODIUM PHOSPHATE 2.3 mg/mL · Solution/ Drops · Ophthalmic · Bausch & Lomb Incoporated
NDC 24208-0317-10 · 1 BOTTLE, DROPPER in 1 CARTON / 10 mL in 1 BOTTLE, DROPPER · ANDA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $1.78 per unit over the past year.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 24208-0317-05) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Bausch & Lomb Incoporated | SULFACETAMIDE SODIUM 100 mg/mL; PREDNISOLONE SODIUM PHOSPHATE 2.3 mg/mL | Aug 26, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | SULFACETAMIDE SODIUM 100 mg/mL; PREDNISOLONE SODIUM PHOSPHATE 2.3 mg/mL | Aug 26, 2026 | Sep 2, 2026 |
| Bausch & Lomb Incoporated | SULFACETAMIDE SODIUM 2.3 mg/mL; PREDNISOLONE SODIUM PHOSPHATE 100 mg/mL | Jul 22, 2026 | Aug 19, 2026 |
| NuCare Pharmaceuticals,Inc. | SULFACETAMIDE SODIUM 2.3 mg/mL; PREDNISOLONE SODIUM PHOSPHATE 100 mg/mL | Jul 22, 2026 | Aug 19, 2026 |
| Bausch & Lomb Incoporated | PREDNISOLONE SODIUM PHOSPHATE 2.3 mg/mL; SULFACETAMIDE SODIUM 100 mg/mL | Jul 15, 2026 | Jul 15, 2026 |
| NuCare Pharmaceuticals,Inc. | PREDNISOLONE SODIUM PHOSPHATE 2.3 mg/mL; SULFACETAMIDE SODIUM 100 mg/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Sulfacetamide Sodium and Prednisolone Sodium Phosphate — NDC 24208-0317-10," retrieved September 3, 2026, https://drugdashboards.com/drug/24208031710.
Free to cite with attribution — see how the data is put together.